Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

A GLP-1/glucagon dual agonist induced significant weight loss and improved multiple cardiometabolic parameters for adults ...

A major new clinical trial involving more than 1,600 people has found that a GLP-1 pill form of the drug orforglipron works ...

“In general, we tend to see more weight loss with GLP-1-based medication treatment in patients who are female, those who do ...

A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight ...

This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...

The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...

Subcutaneous injections of an investigational, selective long-acting amylin receptor agonist led to clinically meaningful ...

Patients with plateaued weight loss or who reached their weight-related goals on a GLP-1 receptor agonist were able to ...

Danish healthcare company Novo Nordisk has dropped prices for its weight-loss and diabetes drug Wegoy, the injectable ...

Danish pharma major Novo Nordisk has slashed the price of Wegovy by up to 37%, to take on its key rival Eli Lilly. Here's how ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...